Contact
searchSearch
HMP Global

Pharmacy Learning Network

PharmLaw

PharmLaw
EyePoint Pharmaceuticals Agrees to $4.6 Million False Claims Act Settlement
07/29/2026
Grace Taylor, MS, MA
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has...
07/29/2026
Pharmacy Learning Network
PharmLaw
Florida Laboratory to Pay $9.8 Million to Resolve FCA Allegations Over Physician Compensation
07/22/2026
Grace Taylor, MS, MA
A Florida laboratory agreed to pay $9.8 million to resolve False Claims Act (FCA) allegations involving physician compensation arrangements that allegedly violated the Stark Law, highlighting ongoing federal scrutiny of referral-based...
A Florida laboratory agreed to pay $9.8 million to resolve False Claims Act (FCA) allegations involving physician compensation arrangements that allegedly violated the Stark Law, highlighting ongoing federal scrutiny of referral-based...
A Florida laboratory agreed to...
07/22/2026
Pharmacy Learning Network
PharmLaw
FTC Settlement With Caremark Signals New Compliance Expectations for PBMs
07/15/2026
Hannah Musick
The Federal Trade Commission's (FTC) proposed settlement with CVS Caremark would require significant changes to pharmacy benefit manager (PBM) rebate practices, transparency, formulary management, and pharmacy contracting, signaling evolving...
The Federal Trade Commission's (FTC) proposed settlement with CVS Caremark would require significant changes to pharmacy benefit manager (PBM) rebate practices, transparency, formulary management, and pharmacy contracting, signaling evolving...
The Federal Trade Commission's...
07/15/2026
Pharmacy Learning Network
PharmLaw
Former Done Global CEO, Clinical President Sentenced in Telehealth Adderall Fraud Case
07/08/2026
Grace Taylor, MS, MA
Former executives of Done Global were sentenced to federal prison after convictions in a multimillion-dollar scheme involving unlawful telehealth prescribing of Adderall and health care fraud, according to the US Department of Justice.
Former executives of Done Global were sentenced to federal prison after convictions in a multimillion-dollar scheme involving unlawful telehealth prescribing of Adderall and health care fraud, according to the US Department of Justice.
Former executives of Done Global...
07/08/2026
Pharmacy Learning Network
PharmLaw
DOJ Telemedicine Fraud Case Underscores Compliance Risks for Health Care Organizations
07/01/2026
Hannah Musick
A US Department of Justice (DOJ) enforcement action against a telemedicine company owner underscores continuing regulatory scrutiny of telemedicine prescribing, kickback arrangements, and Medicare billing practices.
A US Department of Justice (DOJ) enforcement action against a telemedicine company owner underscores continuing regulatory scrutiny of telemedicine prescribing, kickback arrangements, and Medicare billing practices.
A US Department of Justice (DOJ)...
07/01/2026
Pharmacy Learning Network

FDA Recalls

News
Lidocaine Hydrochloride Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has...
07/30/2026
Pharmacy Learning Network
News
Glycopyrrolate Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are...
07/30/2026
Pharmacy Learning Network
News
Amlodipine and Olmesartan Medoxomil Tablets Recalled Due to Failed Dissolution Specifications
07/30/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug...
07/30/2026
Pharmacy Learning Network
News
CareOne Carbamide Peroxide Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network
News
Cleviprex Recalled Due to Lack of Sterility Assurance
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for Cleviprex (clevidipine injectable emulsion) due to a lack of assurance of sterility, affecting 44 280 vials.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network

In the News

News
Lidocaine Hydrochloride Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has been issued for over 180 000 vials of lidocaine hydrochloride injections after particulate matter was identified in the product.
A voluntary Class II recall has...
07/30/2026
Pharmacy Learning Network
News
Glycopyrrolate Injection Recalled Due to the Presence of Particulate Matter
07/30/2026
Rebecca Amrick
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are under a voluntary Class II recall after particulate matter was identified in the product, prompting pharmacies to remove the affected product from inventory and secure alternative supplies.
Glycopyrrolate injections are...
07/30/2026
Pharmacy Learning Network
News
Amlodipine and Olmesartan Medoxomil Tablets Recalled Due to Failed Dissolution Specifications
07/30/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for amlodipine and olmesartan medoxomil tablets due to failed dissolution specifications.
The US Food and Drug...
07/30/2026
Pharmacy Learning Network
PharmLaw
EyePoint Pharmaceuticals Agrees to $4.6 Million False Claims Act Settlement
07/29/2026
Grace Taylor, MS, MA
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has agreed to pay $4.6 million to resolve False Claims Act allegations involving DEXYCU marketing practices, highlighting continued federal scrutiny of pharmaceutical manufacturer programs under the Anti-Kickback...
EyePoint Pharmaceuticals has...
07/29/2026
Pharmacy Learning Network
News
CareOne Carbamide Peroxide Recalled Due to Subpotent Drug
07/23/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for CareOne carbamide peroxide due to the drug’s subpotency, affecting 1201 units.
The US Food and Drug...
07/23/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use